On this page: Invitations and submissions | Decisions | Applications | Other consultations, reviews and information | Historical information

Invitations and submissions

• Scheduling advisory committees invitations for public comment
  Notices inviting public submissions on proposed amendments to the Poisons Standard
• Public submissions on scheduling matters
  Public submissions made in response to proposed amendments to the Poisons Standard and the delegate's interim decision

Decisions

• Scheduling delegate's interim decisions & invitations for further comment
  Reasons and an invitation for further public submissions from the applicant and persons who submitted comments
• Scheduling delegate's final decisions
  Reasons for decisions for amendments to the Poisons Standard

Applications

• Modified release paracetamol
  An application to ACSM regarding proposed rescheduling from S2 to S3

Other consultations, reviews and information

• Implementation of decisions and actions following the review of chemical scheduling in relation to cosmetic and fragrance ingredients
  9 November 2021 Update to the summary of decisions and actions published in October 2019.
• An evaluation of the therapeutic value, benefits and risks of methylenedioxymethamphetamine (MDMA) and psilocybin for the treatment of mental, behavioural or developmental disorders
  30 September 2021 Publication of the independent expert review of MDMA and psilocybin.
• Update on the interim decision for nitrous oxide
  20 July 2021 Publication of the interim decision for nitrous oxide has been delayed.
• Update on interim decisions for substances referred to the March 2021 ACMS/ACCS meetings
  30 June 2021 Publication of interim decisions for substances referred to the March 2021 ACMS/ACCS meetings have been delayed.
• Update on Psilocybin and MDMA scheduling
  7 April 2021 The Scheduling Delegate has decided to seek further advice in relation to psilocybin and MDMA
• Independent Expert Panel on MDMA and psilocybin
  5 August 2021 Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin
• Nicotine Regulation Impact Statement (RIS)
  21 December 2020: The RIS is publicly available, in addition to the delegate's final decision on the scheduling of nicotine.
• Consultation: Interim decision of entry of nicotine in the Poisons Standard
  23 September 2020: Information on the proposed changes to nicotine scheduling, what it would mean for consumers, medical practitioners and pharmacists if the interim decision is made final and how to have your say on the proposed changes.
• Targeted consultation: Review of chemical scheduling in relation to cosmetic and fragrance ingredients
  9 October 2019: Through a targeted consultation, the TGA invited the views of a number of stakeholders on proposed options for process improvements relating to the scheduling of cosmetic and consumer product ingredients
• Changes to the way modified release paracetamol products are supplied: questions and answers
  22 August 2019: Information about the final decision regarding scheduling of modified release paracetamol
• Alkyl nitrites consultation
  6 June 2019: Regulatory options for appropriate access and safety controls for alkyl nitrites
• Codeine re-scheduling Regulation Impact Statement (RIS)
  20 December 2016: The RIS and the associated economic modelling report are publicly available, in addition to the delegate's final decision on the rescheduling of codeine

Historical information

• National Drugs & Poisons Schedule Committee
  Records from the NDPSC - scheduling decision-maker prior to 1 July 2010